中環控股(01735.HK):上海云爾愈分別與海鷹醫科及國控器械訂立銷售代理協議
格隆匯2月10日丨中環控股(01735.HK)宣佈,於2022年2月10日,公司附屬公司上海云爾愈醫療器械有限公司("上海云爾愈")分別與無錫海鷹醫療科技股份有限公司("海鷹醫科")及國藥控股醫療器械有限公司("國控器械")訂立銷售代理協議,內容有關海鷹聚焦超聲無創治療設備("該等產品")的銷售代理及市場推廣。
公吿稱,上海云爾愈於中國擁有三類醫療器械經營許可資格,在健康及醫療保健領域擁有豐富的銷售及業務資源。董事會相信,海鷹協議及國控協議(統稱"該等協議")項下所擬及概述的合作,將有助集團利用其在中國的豐富經驗,併為其在中國的健康及醫療業務提供機會。董事會亦相信,該等合作可擴大集團業務範圍、拓寬收入來源及提升財務表現。因此,董事會認為,該等合作將有利於集團未來的發展,亦符合公司及其股東整體利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.